Roche sizes up first BTK inhibitor approval on Phase III MS victory

If fenebrutinib got the FDA go-ahead, it would become the first BTK inhibitor to gain approval in both RMS and PPMS.

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK in…

The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib ...